Welcome to our dedicated page for Silexion Therapeutics Ordinary Shares news (Ticker: SLXN), a resource for investors and traders seeking the latest updates and insights on Silexion Therapeutics Ordinary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Silexion Therapeutics Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Silexion Therapeutics Ordinary Shares's position in the market.
Silexion Therapeutics (NASDAQ: SLXN) has announced significant new data from its Phase 2 trial of LODER™ in non-resectable locally advanced pancreatic cancer (LAPC) patients with KRAS G12D or G12V mutations. The updated analysis shows:
- A 56% objective response rate (ORR) in patients treated with LODER
- ORR increasing to 67% in patients whose tumors became resectable
- A 9.3-month improvement in overall survival compared to chemotherapy alone
The company is also developing SIL-204, a next-generation product targeting a broader range of KRAS mutations, with improved stability and enhanced ability to silence the KRAS oncogene. These findings validate Silexion's oncogene silencing approach in KRAS-driven cancers.
Silexion Therapeutics (NASDAQ: SLXN) is emerging as a disruptive player in precision oncology, developing RNAi therapies for KRAS-driven cancers. Their proprietary LODER™ platform has shown promising results in Phase 2 trials for locally advanced pancreatic cancer, demonstrating a 9.3-month improvement in overall survival when combined with standard chemotherapy.
Silexion's second-generation product, SIL-204, targets a broader range of KRAS mutations and is set to enter Phase 2/3 trials in 2025-2026. The company's innovative approach addresses key challenges in pancreatic cancer treatment, including late detection, aggressive tumor growth, and drug resistance.
With the global precision medicine market projected to reach $470.53 billion by 2034, Silexion's focus on KRAS-driven cancers positions it as a potential acquisition target in a landscape of increasing M&A activity in the oncology space.
Silexion Therapeutics Corp. (SLXN), a clinical-stage oncology-focused biotech company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY.
Key points:
- Company presentation will be available on-demand starting September 9 at 7:00 AM ET
- Management team will be available for one-on-one meetings during the conference
- Investors interested in meetings should contact their H.C. Wainwright representative
- A replay of the presentation will be accessible on Silexion's website for 90 days
This conference provides Silexion an opportunity to showcase its progress and engage with potential investors in the oncology therapeutics sector.
Silexion Therapeutics and Moringa Acquisition Corp have completed their business combination, forming Silexion Therapeutics Corp. The combined company's shares and warrants are set to trade on Nasdaq under tickers "SLXN" and "SLXNW" starting August 16, 2024. This merger, approved by Moringa shareholders on August 6, 2024, aims to provide Silexion with enhanced financial and strategic flexibility to advance its siRNA therapies for cancer treatment.
Following redemptions, 87,722 MACA public shares were exchanged for ordinary shares of the combined company. The transaction marks a significant milestone for Silexion, positioning it to further its mission of revolutionizing cancer treatment and improving patient outcomes.
FAQ
What is the current stock price of Silexion Therapeutics Ordinary Shares (SLXN)?
What is the market cap of Silexion Therapeutics Ordinary Shares (SLXN)?
